Bayer Wins FDA Accelerated Nod for Hyrnuo as Missouri Judge Weighs $7.25 Billion Roundup Deal

FDA grants accelerated approval to Bayer's Hyrnuo for HER2-mutant lung cancer; Barclays lifts target to EUR 70 as $7.25B glyphosate settlement awaits Missouri court.

Bayer's oncology ambitions cleared another regulatory hurdle this month, but the company's legal overhang remains the wildcard that analysts and investors cannot yet price out. The US Food and Drug Administration granted accelerated approval to Sevabertinib — marketed under the brand name Hyrnuo — on 9 September, positioning the drug as a first-line option for adults with locally advanced or metastatic non-squamous non-small cell lung cancer.

Eligibility hinges on an activating HER2/ERBB2-TKD mutation, a subset of lung cancer widely regarded as difficult to treat and short on effective therapies. The accelerated pathway allows Bayer to bring the product to the US market ahead of completed confirmatory trials, a mechanism that speeds patient access while leaving the company on the hook for verifying clinical benefit down the road.

For the Leverkusen-based group, the green light marks the latest addition to a pipeline the company is leaning on to gradually reduce its reliance on the agricultural legacy that has weighed on its valuation for years.

Agribusiness Gets a Biofuel Angle

Beyond the lab, Bayer disclosed a commercial tie-up with Finland's Neste to scale its newgold® winter rapeseed jointly for biofuel production. The arrangement signals a deliberate push into applications outside food production, extending the company's seeds franchise into the renewable fuels value chain. Management did not attach revenue or volume targets to the agreement.

Wall Street Turns More Constructive

Analysts responded warmly to the run of news. Barclays raised its price target on Bayer on 8 September to EUR 70 from EUR 60, keeping an "Overweight" rating. Deutsche Bank Research followed a day later, reaffirming its "Buy" call with a EUR 60 target. Both houses see meaningful upside from prevailing levels.

The stock traded at EUR 49.13 in pre-market activity, essentially flat against Thursday's close of EUR 49.11. Over twelve months the shares have climbed 78%, with a 33% gain since the start of the year. The paper still sits 8.8% below its 52-week high of EUR 53.86, touched in early July.

Missouri Courtroom Holds the Key

The unresolved piece is glyphosate. Monsanto, Bayer's US subsidiary, pressed a Missouri court last Monday for final approval of a $7.25 billion settlement intended to resolve a portion of the cancer claims tied to its Roundup weedkiller. According to Reuters, Bayer faces roughly 65,000 lawsuits across US state and federal courts. A judicial sign-off would make the legal exposure at least partly quantifiable — but that approval has not yet been granted.

That leaves investors weighing two diverging tracks: tangible operational progress in oncology and biofuels, rewarded by rising price targets, against a litigation file whose final chapter is still being written in a Missouri courtroom.